AI Engines For more Details: Perplexity Kagi Labs You
Glaucoma Management: Brinzolamide belongs to a class of medications known as carbonic anhydrase inhibitors, which work by reducing the production of aqueous humor, the fluid inside the eye. By decreasing the production of aqueous humor, brinzolamide helps to lower intraocular pressure, which is important for managing conditions such as glaucoma and ocular hypertension.
Open-Angle Glaucoma: Open-angle glaucoma is a chronic eye condition characterized by increased pressure within the eye, which can lead to optic nerve damage and vision loss if left untreated. Brinzolamide is often prescribed as eye drops to help lower intraocular pressure and reduce the risk of vision loss associated with open-angle glaucoma.
Ocular Hypertension: Ocular hypertension refers to elevated intraocular pressure without evidence of optic nerve damage or visual field loss. It is considered a risk factor for the development of glaucoma. Brinzolamide eye drops can be used to lower intraocular pressure in patients with ocular hypertension to reduce the risk of progression to glaucoma.
Combination Therapy: Brinzolamide is available in combination with other medications, such as brimonidine, under the brand name Simbrinza. This combination eye drop is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy or require additional IOP reduction.
Mechanism of Action: Brinzolamide works by inhibiting the enzyme carbonic anhydrase in the ciliary body of the eye, which reduces the production of bicarbonate ions and subsequently decreases the secretion of aqueous humor into the eye. By decreasing the production of aqueous humor, brinzolamide helps to lower intraocular pressure.
Administration: Brinzolamide is typically administered as eye drops, which are instilled into the affected eye(s) according to the prescribed dosage regimen. It is important for patients to follow the instructions provided by their healthcare provider regarding the frequency and administration of brinzolamide eye drops to achieve optimal therapeutic effects.
Side Effects: Common side effects associated with brinzolamide eye drops may include blurred vision, eye irritation or discomfort, bitter taste in the mouth, and dry eyes. These side effects are usually mild and transient. However, patients should report any persistent or bothersome side effects to their healthcare provider.
Contraindications: Brinzolamide is contraindicated in patients with a history of hypersensitivity to brinzolamide or other sulfonamide derivatives. It should be used with caution in patients with certain medical conditions, such as severe renal impairment.
Monitoring: Patients receiving brinzolamide therapy may require periodic monitoring of intraocular pressure and ocular health to assess the effectiveness of treatment and detect any potential adverse effects.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
Acne | 0.3 | 0.5 | -0.67 |
ADHD | 4.3 | 0.6 | 6.17 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 3 | 2.6 | 0.15 |
Allergies | 6.3 | 3.1 | 1.03 |
Allergy to milk products | 1.9 | 1.6 | 0.19 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 5.3 | 4.8 | 0.1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.4 | 1.1 | 2.09 |
Ankylosing spondylitis | 3.5 | 1.1 | 2.18 |
Anorexia Nervosa | 1.6 | 2.4 | -0.5 |
Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
Asthma | 4.5 | 3.3 | 0.36 |
Atherosclerosis | 1.4 | 1.6 | -0.14 |
Atrial fibrillation | 2.9 | 1.6 | 0.81 |
Autism | 8.3 | 7.5 | 0.11 |
Autoimmune Disease | 1.2 | 1 | 0.2 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1.2 | 1.2 | |
Bipolar Disorder | 2.1 | 1.4 | 0.5 |
Brain Trauma | 0.9 | 1.4 | -0.56 |
Breast Cancer | 0.5 | 0.3 | 0.67 |
Cancer (General) | 0.6 | 2.2 | -2.67 |
Carcinoma | 3.8 | 2.6 | 0.46 |
Celiac Disease | 1.4 | 3.8 | -1.71 |
Cerebral Palsy | 1.7 | 1.3 | 0.31 |
Chronic Fatigue Syndrome | 3.9 | 4.2 | -0.08 |
Chronic Kidney Disease | 4.1 | 1.7 | 1.41 |
Chronic Lyme | 0.6 | 0.8 | -0.33 |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.4 | -0.4 |
Chronic Urticaria (Hives) | 1.6 | 0.7 | 1.29 |
Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
Cognitive Function | 3.6 | 1.6 | 1.25 |
Colorectal Cancer | 6.9 | 1.8 | 2.83 |
Constipation | 1.5 | 1.3 | 0.15 |
Coronary artery disease | 1.8 | 1.6 | 0.13 |
COVID-19 | 9.7 | 9.4 | 0.03 |
Crohn's Disease | 5.5 | 5.1 | 0.08 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.8 | 1.9 | -1.37 |
d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
deep vein thrombosis | 2.1 | 1.4 | 0.5 |
Denture Wearers Oral Shifts | 0.9 | 0.9 | |
Depression | 8.4 | 8.2 | 0.02 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 1.5 | 1.4 | 0.07 |
Endometriosis | 2.8 | 1.9 | 0.47 |
Eosinophilic Esophagitis | 0.6 | -0.6 | |
Epilepsy | 2.7 | 2.5 | 0.08 |
erectile dysfunction | 1.9 | 0.3 | 5.33 |
Fibromyalgia | 3.4 | 0.8 | 3.25 |
Functional constipation / chronic idiopathic constipation | 4.4 | 2.9 | 0.52 |
gallstone disease (gsd) | 2.9 | 1.2 | 1.42 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 1.2 | -3 |
Generalized anxiety disorder | 2.3 | 2.5 | -0.09 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 2.2 | 0.8 | 1.75 |
Graves' disease | 1.9 | 3 | -0.58 |
Gulf War Syndrome | 0.6 | 1.7 | -1.83 |
Halitosis | 0.9 | 0.3 | 2 |
Hashimoto's thyroiditis | 3 | 1.4 | 1.14 |
Heart Failure | 3.7 | 1.6 | 1.31 |
hemorrhagic stroke | 1 | 1 | |
Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
High Histamine/low DAO | 1.2 | 0.6 | 1 |
hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | 0 |
hyperglycemia | 2 | 2.1 | -0.05 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 5.1 | 5.3 | -0.04 |
Hypothyroidism | 0.3 | 0.7 | -1.33 |
Hypoxia | 3.2 | 0.3 | 9.67 |
IgA nephropathy (IgAN) | 1.6 | 3.8 | -1.37 |
Inflammatory Bowel Disease | 7.4 | 6.7 | 0.1 |
Insomnia | 1.6 | 3.1 | -0.94 |
Intelligence | 0.7 | 0.7 | |
Intracranial aneurysms | 1.2 | 0.6 | 1 |
Irritable Bowel Syndrome | 7.1 | 4.8 | 0.48 |
ischemic stroke | 3.1 | 1.4 | 1.21 |
Liver Cirrhosis | 6.3 | 4.5 | 0.4 |
Long COVID | 5.5 | 7.4 | -0.35 |
Low bone mineral density | 0.8 | -0.8 | |
Lung Cancer | 1 | 1.7 | -0.7 |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
ME/CFS with IBS | 0.6 | 1.8 | -2 |
ME/CFS without IBS | 1.4 | 1.8 | -0.29 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 2.1 | 0.9 | 1.33 |
Metabolic Syndrome | 6.2 | 6.8 | -0.1 |
Mood Disorders | 9.2 | 6.8 | 0.35 |
multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
Multiple Sclerosis | 6.3 | 4 | 0.57 |
Multiple system atrophy (MSA) | 1.8 | 0.7 | 1.57 |
myasthenia gravis | 0.9 | 0.7 | 0.29 |
neuropathic pain | 0.3 | 3.4 | -10.33 |
Neuropathy (all types) | 1 | 2.7 | -1.7 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.2 | 4.9 | 0.06 |
NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
Obesity | 9.8 | 7.1 | 0.38 |
obsessive-compulsive disorder | 4.4 | 2.9 | 0.52 |
Osteoarthritis | 2.3 | 1.5 | 0.53 |
Osteoporosis | 2.5 | 1.9 | 0.32 |
pancreatic cancer | 0.6 | 0.3 | 1 |
Parkinson's Disease | 7.5 | 4.6 | 0.63 |
Polycystic ovary syndrome | 4.4 | 2.9 | 0.52 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
Primary sclerosing cholangitis | 2.4 | 1.8 | 0.33 |
Psoriasis | 3.3 | 1.9 | 0.74 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.8 | 2.9 | 1.34 |
Rosacea | 0.8 | 1 | -0.25 |
Schizophrenia | 6.1 | 3.1 | 0.97 |
scoliosis | 0.2 | 0.9 | -3.5 |
Sjögren syndrome | 2.6 | 2.3 | 0.13 |
Sleep Apnea | 1.6 | 1.6 | 0 |
Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.6 | 1.17 |
Stress / posttraumatic stress disorder | 2.8 | 3 | -0.07 |
Systemic Lupus Erythematosus | 3 | 2 | 0.5 |
Tic Disorder | 0.9 | 1.2 | -0.33 |
Tourette syndrome | 1.2 | 0.3 | 3 |
Type 1 Diabetes | 3.4 | 3.8 | -0.12 |
Type 2 Diabetes | 6.1 | 6.6 | -0.08 |
Ulcerative colitis | 5.1 | 5.6 | -0.1 |
Unhealthy Ageing | 2.9 | 1.9 | 0.53 |
Vitiligo | 1.9 | 1.2 | 0.58 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]